Cogent Biosciences, Inc. Accumulated Other Comprehensive Income
Cogent Biosciences, Inc. (COGT) had Accumulated Other Comprehensive Income of -$770.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$770.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$415.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $355.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $208.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$770.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | -$415.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $355.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | $208.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $13.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $164.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $447.00K 10-K · filed 2026-02-17 |
| 2024-09-30 | $896.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$192.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$39.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $246.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$172.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$97.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $16.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$104.00K 10-K · filed 2024-02-26 |
| 2022-09-30 | -$163.00K 10-Q · filed 2022-11-14 |
| 2019-03-31 | -$2.00K 10-Q · filed 2019-05-13 |
| 2018-12-31 | -$12.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | -$24.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | -$13.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | -$7.00K 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$16.00K 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |